Gedeon Richter first-quarter 2025 results: growing from a strong base

13 May 2025

Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) has announced its financial results for the first quarter of 2025, sending its shares up 2.2% to 26.46 euros.

The company said that pharmaceutical revenues increased by 10% to 220 billion forint ($603 million) in the quarter. Excluding currency changes (ex-FX), revenue growth was 6%, slightly below the full-year guidance, primarily due to a high base effect (large pre-shipments boosted sales a year ago, mostly in the WHC segments and in the APAC region). According to analysts at Jefferies, this was a touch below consensus with a slower start to the year in some businesses.

CNA revenues increased by 13% YoY on the back of continued robust growth in Vraylar (cariprazine) royalty income (+14%). Reagila (cariprazine) sales were flat YoY, temporarily held back due to delivery schedules and a partner change in Australia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK